Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00360672 · ClinicalTrials.gov registry record · Phase 2
Revlimid in Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
NCT00360672: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00360672 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 27 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00360672, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to find out if Revlimid can help to control the disease in patients with relapsed/refractory acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (MDS) with abnormalities in chromosome number 5. The safety of this treatment will also be studied.
Interventions
- DRUG Revlimid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2009-01 |
| Est. Completion | 2012-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00360672
The ClinicalTrials.gov registry entry for NCT00360672 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Revlimid is the first listed.
NCT00360672 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00360672 about?
NCT00360672 is a clinical study titled "Revlimid in Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome". The goal of this clinical research study is to find out if Revlimid can help to control the disease in patients with relapsed/refractory acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (MDS) with abnormalities in chromosome number 5. The safety of this treatment will also be s...
What is the current status of trial NCT00360672?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2009-01. Estimated completion is 2012-05.
What interventions are being tested in trial NCT00360672?
The interventions under investigation include: Revlimid (DRUG).
Who is sponsoring clinical trial NCT00360672?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.